SAB Biotherapeutics Management
Management criteria checks 4/4
SAB Biotherapeutics' CEO is Samuel Reich, appointed in Jan 2024, has a tenure of less than a year. total yearly compensation is $768.40K, comprised of 45.5% salary and 54.5% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $56.28K. The average tenure of the management team and the board of directors is 2.3 years and 4.3 years respectively.
Key information
Samuel Reich
Chief executive officer
US$768.4k
Total compensation
| CEO salary percentage | 45.5% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
Sep 22
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$768k | US$350k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$985k | US$350k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$3m | US$53k | -US$17m |
Compensation vs Market: Samuel's total compensation ($USD768.40K) is about average for companies of similar size in the US market ($USD677.23K).
Compensation vs Earnings: Samuel's compensation has been consistent with company performance over the past year.
CEO
Samuel Reich (49 yo)
less than a year
Tenure
US$768,396
Compensation
Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | less than a year | US$768.40k | 0.24% $ 56.3k | |
| Co-Founder | 10.7yrs | US$807.76k | 5.67% $ 1.3m | |
| Co-Founder & Independent Director | no data | US$25.00k | 5.63% $ 1.3m | |
| Executive VP & COO | 2.3yrs | US$549.32k | 1.08% $ 256.3k | |
| Executive VP & Chief Medical Officer | 2.3yrs | US$921.58k | 0% $ 0 | |
| Co-Founder & Board Observer | no data | no data | 3.15% $ 747.6k | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs | 3.3yrs | no data | no data |
2.3yrs
Average Tenure
53yo
Average Age
Experienced Management: SABS's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Chairman | 3.8yrs | US$768.40k | 0.24% $ 56.3k | |
| Co-Founder | no data | US$807.76k | 5.67% $ 1.3m | |
| Co-Founder & Independent Director | 10.7yrs | US$25.00k | 5.63% $ 1.3m | |
| Co-Founder & Board Observer | 2.9yrs | no data | 3.15% $ 747.6k | |
| Independent Director | 5.7yrs | US$25.00k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$25.00k | 0.43% $ 101.5k | |
| Independent Vice Chairman | 6.7yrs | US$25.00k | 0.062% $ 14.7k | |
| Independent Director | 1.4yrs | US$26.93k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Clinical Advisory Board & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board & Member of Clinical Advisory Board | 4.7yrs | no data | no data |
4.3yrs
Average Tenure
64yo
Average Age
Experienced Board: SABS's board of directors are considered experienced (4.3 years average tenure).